

TDMS No. 99017 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Diethylamine

CAS Number: 109-89-7

F1_M3

Date Report Requested: 10/23/2008

Time Report Requested: 13:20:12

First Dose M/F: 08/18/03 / 08/18/03

Lab: BNW

C Number: C99017
Lock Date: 08/01/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

TDMS No. 99017 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Diethylamine

CAS Number: 109-89-7

Date Report Requested: 10/23/2008

Time Report Requested: 13:20:12

First Dose M/F: 08/18/03 / 08/18/03

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Diethylamine

MALE MICE

Organ

Adrenal Cortex

Heart

Heart: Artery

Liver

Lung

Nose

Nose: Glands, Respiratory Epithelium

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

Nose: Turbinate

Pituitary Gland: Pars Distalis

Preputial Gland

Skin

Spleen

Stomach, Glandular

Morphology

Accessory Adrenal Cortical Nodule

Hyperplasia

Hypertrophy

Cardiomyopathy

Inflammation

Basophilic Focus

Congestion

Degeneration Fatty

Eosinophilic Focus

Mixed Cell Focus

Tension Lipidosis

Hemorrhage

Infiltration Cellular Histiocyte

Inflammation

Accumulation, Hyaline Droplet

Hyperplasia

Accumulation, Hyaline Droplet

Atrophy

Respiratory Metaplasia

Vacuolization Cytoplasmic

Accumulation, Hyaline Droplet

Metaplasia

Necrosis

Vacuolization Cytoplasmic

Hyperostosis

Hyperplasia

Ectasia

Inflammation

Ulcer

Hematopoietic Cell Proliferation

Hyperplasia

TDMS No. 99017 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Diethylamine

CAS Number: 109-89-7

Date Report Requested: 10/23/2008

Time Report Requested: 13:20:12

First Dose M/F: 08/18/03 / 08/18/03

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Diethylamine

FEMALE MICE

Organ

Adrenal Medulla

Heart

Heart: Capillary

Kidney

Liver

Lymph Node, Mandibular

Nose

Nose: Glands, Respiratory Epithelium

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

Nose: Turbinate

Pituitary Gland: Pars Distalis

Stomach, Forestomach

Thyroid Gland

Uterus: Endometrium

Morphology

Hyperplasia

Cardiomyopathy

Hyperplasia

Metaplasia Osseous

Nephropathy

Basophilic Focus

Hyperplasia Lymphoid

Inflammation

Accumulation, Hyaline Droplet

Hyperplasia

Inflammation Chronic

Accumulation, Hyaline Droplet

Atrophy

Respiratory Metaplasia

Vacuolization Cytoplasmic

Accumulation, Hyaline Droplet

Metaplasia

Necrosis

Ulcer

Hyperostosis

Hyperplasia

Hyperplasia

Inflammation

Cyst

Hyperplasia Cystic

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex
Accessory Adrenal Cortical Nodule**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	3/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	7%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	3/32 (9%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.575	(e)	P=0.120	(e)
POLY 1.5	P=0.564	(e)	P=0.119	(e)
POLY 6	P=0.590	(e)	P=0.121	(e)
COCH-ARM / FISHERS	P=0.549	(e)	P=0.121	(e)
MAX-ISO-POLY-3	P=0.178	(e)	P=0.039*	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex
Hyperplasia**

LESION RATES

OVERALL (a)	10/50 (20%)	12/50 (24%)	4/50 (8%)	5/50 (10%)
POLY-3 RATE (b)	10/43.61	12/45.99	4/43.93	5/45.58
POLY-3 PERCENT (g)	22.9%	26.1%	9.1%	11%
TERMINAL (d)	7/31 (23%)	11/38 (29%)	2/32 (6%)	4/37 (11%)
FIRST INCIDENCE	606	666	484	662

STATISTICAL TESTS

POLY 3	P=0.033N*	P=0.459	P=0.068N	P=0.108N
POLY 1.5	P=0.036N*	P=0.435	P=0.070N	P=0.118N
POLY 6	P=0.029N*	P=0.494	P=0.065N	P=0.096N
COCH-ARM / FISHERS	P=0.042N*	P=0.405	P=0.074N	P=0.131N
MAX-ISO-POLY-3	P=0.050N*	P=0.366	P=0.037N*	P=0.068N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex
Hypertrophy**

LESION RATES

OVERALL (a)	37/50 (74%)	31/50 (62%)	26/50 (52%)	26/50 (52%)
POLY-3 RATE (b)	37/45.60	31/46.69	26/43.64	26/45.37
POLY-3 PERCENT (g)	81.1%	66.4%	59.6%	57.3%
TERMINAL (d)	28/31 (90%)	28/38 (74%)	24/32 (75%)	25/37 (68%)
FIRST INCIDENCE	583	541	609	717

STATISTICAL TESTS

POLY 3	P=0.010N**	P=0.072N	P=0.014N*	P=0.008N**
POLY 1.5	P=0.011N*	P=0.097N	P=0.015N*	P=0.011N*
POLY 6	P=0.008N**	P=0.049N*	P=0.015N*	P=0.005N**
COCH-ARM / FISHERS	P=0.016N*	P=0.142N	P=0.019N*	P=0.019N*
MAX-ISO-POLY-3	P=0.008N**	P=0.045N*	P=0.008N**	P=0.004N**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	1/45.80	1/43.20	0/45.33
POLY-3 PERCENT (g)	0%	2.2%	2.3%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	---	718	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.582N	P=0.513	P=0.502	(e)
POLY 1.5	P=0.589N	P=0.507	P=0.500	(e)
POLY 6	P=0.572N	P=0.522	P=0.504	(e)
COCH-ARM / FISHERS	P=0.597N	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.415N	P=0.175	P=0.160	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Medulla
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	1/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	2.2%	0%	0%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.565N	P=0.513	(e)	(e)
POLY 1.5	P=0.570N	P=0.507	(e)	(e)
POLY 6	P=0.558N	P=0.521	(e)	(e)
COCH-ARM / FISHERS	P=0.575N	P=0.500	(e)	(e)
MAX-ISO-POLY-3	P=0.399N	P=0.174	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Brain
Atrophy**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.14	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	656	---	---	---

STATISTICAL TESTS

POLY 3	P=0.318N	P=0.488N	P=0.500N	P=0.490N
POLY 1.5	P=0.313N	P=0.493N	P=0.500N	P=0.495N
POLY 6	P=0.324N	P=0.481N	P=0.499N	P=0.484N
COCH-ARM / FISHERS	P=0.307N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.123N	P=0.158N	P=0.158N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Epididymis
Granuloma Sperm**

LESION RATES

OVERALL (a)	0/49 (0%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/42.09	1/45.75	0/43.20	2/45.89
POLY-3 PERCENT (g)	0%	2.2%	0%	4.4%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/32 (0%)	1/37 (3%)
FIRST INCIDENCE	---	729 (T)	---	554

STATISTICAL TESTS

POLY 3	P=0.149	P=0.517	(e)	P=0.257
POLY 1.5	P=0.145	P=0.511	(e)	P=0.250
POLY 6	P=0.154	P=0.524	(e)	P=0.266
COCH-ARM / FISHERS	P=0.140	P=0.505	(e)	P=0.253
MAX-ISO-POLY-3	P=0.100	P=0.178	(e)	P=0.094

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Eye
Cataract**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	2/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	4.6%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	2/32 (6%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.625	(e)	P=0.239	(e)
POLY 1.5	P=0.616	(e)	P=0.238	(e)
POLY 6	P=0.638	(e)	P=0.241	(e)
COCH-ARM / FISHERS	P=0.603	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.263	(e)	P=0.077	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Eye: Cornea
Inflammation Chronic

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/42.87	2/45.75	0/43.20	2/45.33
POLY-3 PERCENT (g)	0%	4.4%	0%	4.4%
TERMINAL (d)	0/31 (0%)	2/38 (5%)	0/32 (0%)	2/37 (5%)
FIRST INCIDENCE	---	729 (T)	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.258	P=0.252	(e)	P=0.250
POLY 1.5	P=0.251	P=0.245	(e)	P=0.244
POLY 6	P=0.269	P=0.262	(e)	P=0.258
COCH-ARM / FISHERS	P=0.243	P=0.247	(e)	P=0.247
MAX-ISO-POLY-3	P=0.139	P=0.090	(e)	P=0.088

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Harderian Gland
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	1/45.75	1/43.20	0/45.33
POLY-3 PERCENT (g)	0%	2.2%	2.3%	0%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.582N	P=0.513	P=0.502	(e)
POLY 1.5	P=0.589N	P=0.507	P=0.500	(e)
POLY 6	P=0.572N	P=0.521	P=0.504	(e)
COCH-ARM / FISHERS	P=0.597N	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.415N	P=0.174	P=0.160	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Heart
Cardiomyopathy**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	8/50 (16%)	1/50 (2%)
POLY-3 RATE (b)	0/42.87	1/45.75	8/43.22	1/45.33
POLY-3 PERCENT (g)	0%	2.2%	18.5%	2.2%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	7/32 (22%)	1/37 (3%)
FIRST INCIDENCE	---	729 (T)	723	729 (T)

STATISTICAL TESTS

POLY 3	P=0.329	P=0.513	P=0.004**	P=0.511
POLY 1.5	P=0.313	P=0.507	P=0.004**	P=0.506
POLY 6	P=0.352	P=0.521	P=0.004**	P=0.518
COCH-ARM / FISHERS	P=0.301	P=0.500	P=0.003**	P=0.500
MAX-ISO-POLY-3	P=0.028*	P=0.174	P<0.001**	P=0.172

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Heart: Artery
Inflammation**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	4/50 (8%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	4/46.66
POLY-3 PERCENT (g)	0%	0%	0%	8.6%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	2/37 (5%)
FIRST INCIDENCE	---	---	---	442

STATISTICAL TESTS

POLY 3	P=0.003**	(e)	(e)	P=0.072
POLY 1.5	P=0.003**	(e)	(e)	P=0.067
POLY 6	P=0.003**	(e)	(e)	P=0.079
COCH-ARM / FISHERS	P=0.003**	(e)	(e)	P=0.059
MAX-ISO-POLY-3	P=0.004**	(e)	(e)	P=0.028*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Heart: Atrium
Thrombosis**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	2/46.35	1/43.22	0/45.33
POLY-3 PERCENT (g)	0%	4.3%	2.3%	0%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	536	723	---

STATISTICAL TESTS

POLY 3	P=0.443N	P=0.255	P=0.502	(e)
POLY 1.5	P=0.454N	P=0.247	P=0.501	(e)
POLY 6	P=0.428N	P=0.266	P=0.504	(e)
COCH-ARM / FISHERS	P=0.466N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.343N	P=0.093	P=0.161	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Heart: Capillary
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Intestine Small, Ileum
Inflammation Chronic**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/42.87	2/45.75	1/43.20	0/45.33
POLY-3 PERCENT (g)	2.3%	4.4%	2.3%	0%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.238N	P=0.523	P=0.759N	P=0.489N
POLY 1.5	P=0.244N	P=0.513	P=0.760N	P=0.494N
POLY 6	P=0.230N	P=0.537	P=0.757N	P=0.482N
COCH-ARM / FISHERS	P=0.250N	P=0.500	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.242N	P=0.305	P=0.497N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Islets, Pancreatic
Hyperplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/43.26	1/45.75	1/42.77	0/45.33
POLY-3 PERCENT (g)	4.6%	2.2%	2.3%	0%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	620	729 (T)	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.152N	P=0.480N	P=0.504N	P=0.227N
POLY 1.5	P=0.154N	P=0.489N	P=0.506N	P=0.232N
POLY 6	P=0.151N	P=0.468N	P=0.501N	P=0.220N
COCH-ARM / FISHERS	P=0.154N	P=0.500N	P=0.508N	P=0.247N
MAX-ISO-POLY-3	P=0.122N	P=0.270N	P=0.284N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney
Cyst**

LESION RATES

OVERALL (a)	4/50 (8%)	6/50 (12%)	6/49 (12%)	5/50 (10%)
POLY-3 RATE (b)	4/43.26	6/45.75	6/42.67	5/45.33
POLY-3 PERCENT (g)	9.3%	13.1%	14.1%	11%
TERMINAL (d)	3/31 (10%)	6/38 (16%)	6/32 (19%)	5/37 (14%)
FIRST INCIDENCE	620	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.511	P=0.405	P=0.360	P=0.529
POLY 1.5	P=0.499	P=0.389	P=0.358	P=0.516
POLY 6	P=0.530	P=0.427	P=0.365	P=0.548
COCH-ARM / FISHERS	P=0.483	P=0.370	P=0.357	P=0.500
MAX-ISO-POLY-3	P=0.498	P=0.289	P=0.245	P=0.392

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney
Infarct**

LESION RATES

OVERALL (a)	1/50 (2%)	4/50 (8%)	4/49 (8%)	2/50 (4%)
POLY-3 RATE (b)	1/43.54	4/45.80	4/42.67	2/45.33
POLY-3 PERCENT (g)	2.3%	8.7%	9.4%	4.4%
TERMINAL (d)	0/31 (0%)	3/38 (8%)	4/32 (13%)	2/37 (5%)
FIRST INCIDENCE	503	718	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.545	P=0.194	P=0.172	P=0.514
POLY 1.5	P=0.533	P=0.187	P=0.172	P=0.507
POLY 6	P=0.563	P=0.205	P=0.174	P=0.524
COCH-ARM / FISHERS	P=0.520	P=0.181	P=0.175	P=0.500
MAX-ISO-POLY-3	P=0.260	P=0.098	P=0.080	P=0.296

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney
Metaplasia Osseous**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/49 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/42.87	2/45.75	1/42.67	2/45.58
POLY-3 PERCENT (g)	2.3%	4.4%	2.3%	4.4%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	1/32 (3%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	662

STATISTICAL TESTS

POLY 3	P=0.463	P=0.523	P=0.760	P=0.521
POLY 1.5	P=0.453	P=0.513	P=0.758	P=0.512
POLY 6	P=0.477	P=0.537	P=0.759N	P=0.536
COCH-ARM / FISHERS	P=0.442	P=0.500	P=0.747	P=0.500
MAX-ISO-POLY-3	P=0.486	P=0.305	P=0.498	P=0.303

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney
Nephropathy**

LESION RATES

OVERALL (a)	44/50 (88%)	47/50 (94%)	44/49 (90%)	45/50 (90%)
POLY-3 RATE (b)	44/47.14	47/48.58	44/46.49	45/47.62
POLY-3 PERCENT (g)	93.3%	96.8%	94.6%	94.5%
TERMINAL (d)	31/31 (100%)	38/38 (100%)	32/32 (100%)	36/37 (97%)
FIRST INCIDENCE	491	536	442	563

STATISTICAL TESTS

POLY 3	P=0.595	P=0.350	P=0.588	P=0.596
POLY 1.5	P=0.556	P=0.284	P=0.540	P=0.532
POLY 6	P=0.591N	P=0.552	P=0.730	P=0.758
COCH-ARM / FISHERS	P=0.548	P=0.243	P=0.514	P=0.500
MAX-ISO-POLY-3	P=0.469	P=0.162	P=0.365	P=0.382

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Larynx
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Basophilic Focus**

LESION RATES

OVERALL (a)	5/50 (10%)	13/50 (26%)	10/50 (20%)	8/50 (16%)
POLY-3 RATE (b)	5/43.53	13/47.05	10/43.39	8/45.88
POLY-3 PERCENT (g)	11.5%	27.6%	23.1%	17.4%
TERMINAL (d)	3/31 (10%)	10/38 (26%)	9/32 (28%)	7/37 (19%)
FIRST INCIDENCE	620	484	678	555

STATISTICAL TESTS

POLY 3	P=0.495	P=0.046*	P=0.125	P=0.310
POLY 1.5	P=0.473	P=0.040*	P=0.127	P=0.295
POLY 6	P=0.524	P=0.056	P=0.124	P=0.331
COCH-ARM / FISHERS	P=0.447	P=0.033*	P=0.131	P=0.277
MAX-ISO-POLY-3	P=0.153	P=0.030*	P=0.075	P=0.219

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver
Clear Cell Focus

LESION RATES

OVERALL (a)	5/50 (10%)	5/50 (10%)	7/50 (14%)	2/50 (4%)
POLY-3 RATE (b)	5/42.87	5/45.75	7/43.20	2/45.33
POLY-3 PERCENT (g)	11.7%	10.9%	16.2%	4.4%
TERMINAL (d)	5/31 (16%)	5/38 (13%)	7/32 (22%)	2/37 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.172N	P=0.589N	P=0.383	P=0.194N
POLY 1.5	P=0.182N	P=0.607N	P=0.380	P=0.204N
POLY 6	P=0.159N	P=0.562N	P=0.390	P=0.179N
COCH-ARM / FISHERS	P=0.194N	P=0.630N	P=0.380	P=0.218N
MAX-ISO-POLY-3	P=0.167N	P=0.457N	P=0.273	P=0.110N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Congestion**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.08	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	676	---	---	---

STATISTICAL TESTS

POLY 3	P=0.120N	P=0.224N	P=0.236N	P=0.226N
POLY 1.5	P=0.117N	P=0.230N	P=0.237N	P=0.231N
POLY 6	P=0.124N	P=0.216N	P=0.235N	P=0.219N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.076N	P=0.076N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver
Cyst

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Degeneration Fatty**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.14	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	656	---	---	---

STATISTICAL TESTS

POLY 3	P=0.120N	P=0.224N	P=0.237N	P=0.226N
POLY 1.5	P=0.117N	P=0.230N	P=0.237N	P=0.231N
POLY 6	P=0.124N	P=0.216N	P=0.235N	P=0.219N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.076N	P=0.076N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Eosinophilic Focus**

LESION RATES

OVERALL (a)	2/50 (4%)	8/50 (16%)	6/50 (12%)	7/50 (14%)
POLY-3 RATE (b)	2/43.26	8/45.75	6/43.89	7/45.37
POLY-3 PERCENT (g)	4.6%	17.5%	13.7%	15.4%
TERMINAL (d)	1/31 (3%)	8/38 (21%)	4/32 (13%)	6/37 (16%)
FIRST INCIDENCE	620	729 (T)	506	717

STATISTICAL TESTS

POLY 3	P=0.174	P=0.054	P=0.136	P=0.090
POLY 1.5	P=0.164	P=0.050*	P=0.135	P=0.085
POLY 6	P=0.189	P=0.061	P=0.139	P=0.098
COCH-ARM / FISHERS	P=0.154	P=0.046*	P=0.134	P=0.080
MAX-ISO-POLY-3	P=0.104	P=0.029*	P=0.072	P=0.048*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Mixed Cell Focus**

LESION RATES

OVERALL (a)	0/50 (0%)	4/50 (8%)	1/50 (2%)	5/50 (10%)
POLY-3 RATE (b)	0/42.87	4/45.75	1/43.22	5/45.37
POLY-3 PERCENT (g)	0%	8.7%	2.3%	11%
TERMINAL (d)	0/31 (0%)	4/38 (11%)	0/32 (0%)	4/37 (11%)
FIRST INCIDENCE	---	729 (T)	723	717

STATISTICAL TESTS

POLY 3	P=0.053	P=0.069	P=0.502	P=0.035*
POLY 1.5	P=0.050*	P=0.065	P=0.501	P=0.033*
POLY 6	P=0.058	P=0.075	P=0.504	P=0.039*
COCH-ARM / FISHERS	P=0.048*	P=0.059	P=0.500	P=0.028*
MAX-ISO-POLY-3	P=0.021*	P=0.026*	P=0.161	P=0.013*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver
Necrosis

LESION RATES

OVERALL (a)	4/50 (8%)	1/50 (2%)	4/50 (8%)	3/50 (6%)
POLY-3 RATE (b)	4/43.77	1/45.75	4/43.92	3/45.37
POLY-3 PERCENT (g)	9.1%	2.2%	9.1%	6.6%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	2/32 (6%)	2/37 (5%)
FIRST INCIDENCE	583	729 (T)	618	717

STATISTICAL TESTS

POLY 3	P=0.571N	P=0.165N	P=0.642N	P=0.480N
POLY 1.5	P=0.573N	P=0.171N	P=0.643N	P=0.489N
POLY 6	P=0.568N	P=0.157N	P=0.638N	P=0.468N
COCH-ARM / FISHERS	P=0.576N	P=0.181N	P=0.643N	P=0.500N
MAX-ISO-POLY-3	P=0.444N	P=0.080N	P=0.497N	P=0.332N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Tension Lipidosis**

LESION RATES

OVERALL (a)	1/50 (2%)	6/50 (12%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	1/43.26	6/45.75	2/43.61	3/45.33
POLY-3 PERCENT (g)	2.3%	13.1%	4.6%	6.6%
TERMINAL (d)	0/31 (0%)	6/38 (16%)	1/32 (3%)	3/37 (8%)
FIRST INCIDENCE	620	729 (T)	610	729 (T)

STATISTICAL TESTS

POLY 3	P=0.524	P=0.065	P=0.503	P=0.322
POLY 1.5	P=0.510	P=0.061	P=0.501	P=0.315
POLY 6	P=0.544	P=0.071	P=0.507	P=0.333
COCH-ARM / FISHERS	P=0.494	P=0.056	P=0.500	P=0.309
MAX-ISO-POLY-3	P=0.227	P=0.031*	P=0.283	P=0.172

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung
Hemorrhage**

LESION RATES

OVERALL (a)	3/50 (6%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/43.30	0/45.75	2/43.22	1/45.33
POLY-3 PERCENT (g)	6.9%	0%	4.6%	2.2%
TERMINAL (d)	2/31 (7%)	0/38 (0%)	1/32 (3%)	1/37 (3%)
FIRST INCIDENCE	606	---	723	729 (T)

STATISTICAL TESTS

POLY 3	P=0.334N	P=0.109N	P=0.501N	P=0.289N
POLY 1.5	P=0.334N	P=0.113N	P=0.501N	P=0.296N
POLY 6	P=0.335N	P=0.103N	P=0.499N	P=0.278N
COCH-ARM / FISHERS	P=0.333N	P=0.121N	P=0.500N	P=0.309N
MAX-ISO-POLY-3	P=0.182N	P=0.038N*	P=0.324N	P=0.148N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung
Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	12/50 (24%)	1/50 (2%)	7/50 (14%)	3/50 (6%)
POLY-3 RATE (b)	12/43.99	1/45.99	7/44.20	3/45.82
POLY-3 PERCENT (g)	27.3%	2.2%	15.8%	6.6%
TERMINAL (d)	7/31 (23%)	0/38 (0%)	3/32 (9%)	2/37 (5%)
FIRST INCIDENCE	609	666	506	581

STATISTICAL TESTS

POLY 3	P=0.026N*	P<0.001N**	P=0.146N	P=0.008N**
POLY 1.5	P=0.027N*	P<0.001N**	P=0.149N	P=0.009N**
POLY 6	P=0.025N*	P<0.001N**	P=0.141N	P=0.006N**
COCH-ARM / FISHERS	P=0.031N*	P<0.001N**	P=0.154N	P=0.011N*
MAX-ISO-POLY-3	P=0.002N**	P<0.001N**	P=0.095N	P=0.004N**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung: Alveolar Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	3/50 (6%)	2/50 (4%)	5/50 (10%)	2/50 (4%)
POLY-3 RATE (b)	3/43.56	2/46.34	5/43.20	2/45.33
POLY-3 PERCENT (g)	6.9%	4.3%	11.6%	4.4%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	5/32 (16%)	2/37 (5%)
FIRST INCIDENCE	609	541	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.487N	P=0.472N	P=0.351	P=0.482N
POLY 1.5	P=0.491N	P=0.484N	P=0.353	P=0.490N
POLY 6	P=0.480N	P=0.456N	P=0.350	P=0.471N
COCH-ARM / FISHERS	P=0.496N	P=0.500N	P=0.357	P=0.500N
MAX-ISO-POLY-3	P=0.456N	P=0.304N	P=0.227	P=0.311N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung: Arteriole
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	2/46.35	1/43.22	0/45.33
POLY-3 PERCENT (g)	0%	4.3%	2.3%	0%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	536	723	---

STATISTICAL TESTS

POLY 3	P=0.443N	P=0.255	P=0.502	(e)
POLY 1.5	P=0.454N	P=0.247	P=0.501	(e)
POLY 6	P=0.428N	P=0.266	P=0.504	(e)
COCH-ARM / FISHERS	P=0.466N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.343N	P=0.093	P=0.161	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lymph Node, Mandibular
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/16 (0%)	0/20 (0%)	0/18 (0%)	0/20 (0%)
POLY-3 RATE (b)	0/13.36	0/17.77	0/15.29	0/18.26
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/13 (0%)	0/11 (0%)	0/14 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lymph Node, Mesenteric
Infiltration Cellular**

LESION RATES

OVERALL (a)	2/49 (4%)	3/47 (6%)	1/48 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/42.92	3/43.42	1/41.77	0/45.33
POLY-3 PERCENT (g)	4.7%	6.9%	2.4%	0%
TERMINAL (d)	0/30 (0%)	1/36 (3%)	1/31 (3%)	0/37 (0%)
FIRST INCIDENCE	509	620	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.097N	P=0.505	P=0.510N	P=0.225N
POLY 1.5	P=0.100N	P=0.494	P=0.509N	P=0.229N
POLY 6	P=0.094N	P=0.523	P=0.509N	P=0.219N
COCH-ARM / FISHERS	P=0.102N	P=0.480	P=0.508N	P=0.242N
MAX-ISO-POLY-3	P=0.114N	P=0.331	P=0.290N	P=0.075N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Mesentery
Inflammation Chronic**

LESION RATES

OVERALL (a)	2/10 (20%)	1/6 (17%)	1/4 (25%)	1/8 (13%)
POLY-3 RATE (b)	2/9.06	1/5.70	1/2.88	1/7.75
POLY-3 PERCENT (g)	22.1%	17.5%	34.8%	12.9%
TERMINAL (d)	0/4 (0%)	1/5 (20%)	0/1 (0%)	1/7 (14%)
FIRST INCIDENCE	584	729 (T)	723	729 (T)

STATISTICAL TESTS

POLY 3	P=0.460N	P=0.666N	P=0.621	P=0.557N
POLY 1.5	P=0.468N	P=0.672N	P=0.647	P=0.567N
POLY 6	P=0.448N	P=0.659N	P=0.592	P=0.543N
COCH-ARM / FISHERS	P=0.474N	P=0.696N	P=0.670	P=0.588N
MAX-ISO-POLY-3	P=0.508N	P=0.426N	P=0.379	P=0.323N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Mesentery: Fat
Necrosis**

LESION RATES

OVERALL (a)	5/10 (50%)	4/6 (67%)	1/4 (25%)	4/8 (50%)
POLY-3 RATE (b)	5/9.67	4/5.70	1/2.85	4/8.00
POLY-3 PERCENT (g)	51.7%	70.2%	35.1%	50%
TERMINAL (d)	2/4 (50%)	4/5 (80%)	1/1 (100%)	3/7 (43%)
FIRST INCIDENCE	561	729 (T)	729 (T)	662

STATISTICAL TESTS

POLY 3	P=0.498N	P=0.433	P=0.564N	P=0.651N
POLY 1.5	P=0.505N	P=0.441	P=0.497N	P=0.662N
POLY 6	P=0.476N	P=0.423	P=0.638N	P=0.631N
COCH-ARM / FISHERS	P=0.504N	P=0.451	P=0.406N	P=0.681N
MAX-ISO-POLY-3	P=0.494N	P=0.271	P=0.366N	P=0.473N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose
Inflammation**

LESION RATES

OVERALL (a)	6/50 (12%)	5/50 (10%)	6/50 (12%)	14/50 (28%)
POLY-3 RATE (b)	6/44.16	5/46.89	6/44.64	14/46.35
POLY-3 PERCENT (g)	13.6%	10.7%	13.4%	30.2%
TERMINAL (d)	3/31 (10%)	2/38 (5%)	2/32 (6%)	12/37 (32%)
FIRST INCIDENCE	589	484	506	442

STATISTICAL TESTS

POLY 3	P=0.009**	P=0.458N	P=0.614N	P=0.047*
POLY 1.5	P=0.009**	P=0.476N	P=0.616N	P=0.043*
POLY 6	P=0.009**	P=0.435N	P=0.610N	P=0.052
COCH-ARM / FISHERS	P=0.010**	P=0.500N	P=0.620N	P=0.039*
MAX-ISO-POLY-3	P=0.014*	P=0.339N	P=0.491N	P=0.029*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Glands, Respiratory Epithelium
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	5/50 (10%)	5/50 (10%)	16/50 (32%)	33/50 (66%)
POLY-3 RATE (b)	5/43.26	5/46.47	16/44.53	33/48.10
POLY-3 PERCENT (g)	11.6%	10.8%	35.9%	68.6%
TERMINAL (d)	4/31 (13%)	3/38 (8%)	10/32 (31%)	25/37 (68%)
FIRST INCIDENCE	620	561	609	442

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.585N	P=0.006**	P<0.001**
POLY 1.5	P<0.001**	P=0.605N	P=0.006**	P<0.001**
POLY 6	P<0.001**	P=0.556N	P=0.007**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.630N	P=0.006**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.453N	P=0.003**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Glands, Respiratory Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	42/50 (84%)	41/50 (82%)	44/50 (88%)	50/50 (100%)
POLY-3 RATE (b)	42/48.44	41/49.88	44/48.59	50/50.00
POLY-3 PERCENT (g)	86.7%	82.2%	90.6%	100%
TERMINAL (d)	26/31 (84%)	31/38 (82%)	29/32 (91%)	37/37 (100%)
FIRST INCIDENCE	491	484	484	442

STATISTICAL TESTS

POLY 3	P=0.004**	P=0.366N	P=0.386	P=0.007**
POLY 1.5	P=0.003**	P=0.420N	P=0.382	P=0.005**
POLY 6	P=0.005**	P=0.308N	P=0.395	P=0.012*
COCH-ARM / FISHERS	P=0.003**	P=0.500N	P=0.387	P=0.003**
MAX-ISO-POLY-3	P=0.005**	P=0.269N	P=0.266	P=0.002**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Glands, Respiratory Epithelium
Inflammation Chronic**

LESION RATES

OVERALL (a)	6/50 (12%)	9/50 (18%)	8/50 (16%)	11/50 (22%)
POLY-3 RATE (b)	6/43.67	9/47.00	8/43.39	11/47.23
POLY-3 PERCENT (g)	13.7%	19.2%	18.4%	23.3%
TERMINAL (d)	3/31 (10%)	7/38 (18%)	6/32 (19%)	6/37 (16%)
FIRST INCIDENCE	606	484	705	442

STATISTICAL TESTS

POLY 3	P=0.171	P=0.342	P=0.380	P=0.184
POLY 1.5	P=0.157	P=0.319	P=0.382	P=0.166
POLY 6	P=0.191	P=0.371	P=0.380	P=0.211
COCH-ARM / FISHERS	P=0.139	P=0.288	P=0.387	P=0.143
MAX-ISO-POLY-3	P=0.211	P=0.253	P=0.277	P=0.130

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	7/50 (14%)	2/50 (4%)	4/50 (8%)	6/50 (12%)
POLY-3 RATE (b)	7/43.30	2/46.30	4/44.76	6/45.81
POLY-3 PERCENT (g)	16.2%	4.3%	8.9%	13.1%
TERMINAL (d)	6/31 (19%)	1/38 (3%)	0/32 (0%)	5/37 (14%)
FIRST INCIDENCE	606	561	442	583

STATISTICAL TESTS

POLY 3	P=0.530	P=0.063N	P=0.241N	P=0.456N
POLY 1.5	P=0.526	P=0.070N	P=0.250N	P=0.476N
POLY 6	P=0.536	P=0.055N	P=0.228N	P=0.428N
COCH-ARM / FISHERS	P=0.520	P=0.080N	P=0.262N	P=0.500N
MAX-ISO-POLY-3	P=0.217N	P=0.034N*	P=0.156N	P=0.345N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium
Atrophy**

LESION RATES

OVERALL (a)	9/50 (18%)	19/50 (38%)	50/50 (100%)	50/50 (100%)
POLY-3 RATE (b)	9/44.17	19/46.80	50/50.00	50/50.00
POLY-3 PERCENT (g)	20.4%	40.6%	100%	100%
TERMINAL (d)	6/31 (19%)	15/38 (40%)	32/32 (100%)	37/37 (100%)
FIRST INCIDENCE	584	561	442	442

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.028*	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.025*	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.035*	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.022*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.019*	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium
Necrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	2/46.84	0/43.20	0/45.33
POLY-3 PERCENT (g)	0%	4.3%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	484	---	---

STATISTICAL TESTS

POLY 3	P=0.393N	P=0.257	(e)	(e)
POLY 1.5	P=0.402N	P=0.249	(e)	(e)
POLY 6	P=0.379N	P=0.270	(e)	(e)
COCH-ARM / FISHERS	P=0.415N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.269N	P=0.095	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium
Respiratory Metaplasia**

LESION RATES

OVERALL (a)	14/50 (28%)	15/50 (30%)	44/50 (88%)	50/50 (100%)
POLY-3 RATE (b)	14/43.36	15/48.10	44/49.10	50/50.00
POLY-3 PERCENT (g)	32.3%	31.2%	89.6%	100%
TERMINAL (d)	12/31 (39%)	9/38 (24%)	28/32 (88%)	37/37 (100%)
FIRST INCIDENCE	589	484	442	442

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.545N	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.576	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.468N	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.456N	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	5/50 (10%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	5/46.95	3/44.20	0/45.33
POLY-3 PERCENT (g)	0%	10.7%	6.8%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	536	609	---

STATISTICAL TESTS

POLY 3	P=0.278N	P=0.039*	P=0.124	(e)
POLY 1.5	P=0.295N	P=0.035*	P=0.121	(e)
POLY 6	P=0.255N	P=0.045*	P=0.129	(e)
COCH-ARM / FISHERS	P=0.318N	P=0.028*	P=0.121	(e)
MAX-ISO-POLY-3	P=0.146N	P=0.016*	P=0.042*	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	11/50 (22%)	6/50 (12%)	19/50 (38%)	30/50 (60%)
POLY-3 RATE (b)	11/44.57	6/47.00	19/46.01	30/48.50
POLY-3 PERCENT (g)	24.7%	12.8%	41.3%	61.9%
TERMINAL (d)	7/31 (23%)	4/38 (11%)	11/32 (34%)	21/37 (57%)
FIRST INCIDENCE	589	484	442	442

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.114N	P=0.069	P<0.001**
POLY 1.5	P<0.001**	P=0.126N	P=0.065	P<0.001**
POLY 6	P<0.001**	P=0.102N	P=0.076	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.143N	P=0.063	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.075N	P=0.046*	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium
Metaplasia**

LESION RATES

OVERALL (a)	4/50 (8%)	7/50 (14%)	16/50 (32%)	34/50 (68%)
POLY-3 RATE (b)	4/44.16	7/47.12	16/43.74	34/48.18
POLY-3 PERCENT (g)	9.1%	14.9%	36.6%	70.6%
TERMINAL (d)	1/31 (3%)	3/38 (8%)	12/32 (38%)	25/37 (68%)
FIRST INCIDENCE	589	484	678	554

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.299	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.283	P=0.002**	P<0.001**
POLY 6	P<0.001**	P=0.321	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.262	P=0.003**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.206	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium
Necrosis**

LESION RATES

OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	8/50 (16%)
POLY-3 RATE (b)	2/43.77	3/46.58	3/43.29	8/46.18
POLY-3 PERCENT (g)	4.6%	6.4%	6.9%	17.3%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	2/32 (6%)	5/37 (14%)
FIRST INCIDENCE	589	484	705	563

STATISTICAL TESTS

POLY 3	P=0.018*	P=0.528	P=0.495	P=0.054
POLY 1.5	P=0.017*	P=0.516	P=0.496	P=0.050*
POLY 6	P=0.019*	P=0.544	P=0.494	P=0.060
COCH-ARM / FISHERS	P=0.017*	P=0.500	P=0.500	P=0.046*
MAX-ISO-POLY-3	P=0.027*	P=0.353	P=0.320	P=0.029*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium
Ulcer**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	2/50 (4%)	4/50 (8%)
POLY-3 RATE (b)	1/43.30	1/46.46	2/43.32	4/45.59
POLY-3 PERCENT (g)	2.3%	2.2%	4.6%	8.8%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	3/37 (8%)
FIRST INCIDENCE	606	484	705	659

STATISTICAL TESTS

POLY 3	P=0.075	P=0.745N	P=0.500	P=0.194
POLY 1.5	P=0.074	P=0.752N	P=0.499	P=0.187
POLY 6	P=0.078	P=0.736N	P=0.502	P=0.205
COCH-ARM / FISHERS	P=0.072	P=0.753N	P=0.500	P=0.181
MAX-ISO-POLY-3	P=0.115	P=0.480N	P=0.280	P=0.098

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	1/45.93	3/43.78	0/45.33
POLY-3 PERCENT (g)	0%	2.2%	6.9%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	---	684	618	---

STATISTICAL TESTS

POLY 3	P=0.610N	P=0.514	P=0.122	(e)
POLY 1.5	P=0.620N	P=0.508	P=0.120	(e)
POLY 6	P=0.596N	P=0.523	P=0.126	(e)
COCH-ARM / FISHERS	P=0.631N	P=0.500	P=0.121	(e)
MAX-ISO-POLY-3	P=0.240	P=0.175	P=0.041*	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Turbinate
Hyperostosis**

LESION RATES

OVERALL (a)	5/50 (10%)	23/50 (46%)	50/50 (100%)	50/50 (100%)
POLY-3 RATE (b)	5/43.35	23/47.89	50/50.00	50/50.00
POLY-3 PERCENT (g)	11.5%	48%	100%	100%
TERMINAL (d)	3/31 (10%)	17/38 (45%)	32/32 (100%)	37/37 (100%)
FIRST INCIDENCE	620	484	442	442

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Turbinate
Necrosis**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	1/43.30	0/45.75	0/43.20	3/45.59
POLY-3 PERCENT (g)	2.3%	0%	0%	6.6%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	2/37 (5%)
FIRST INCIDENCE	606	---	---	659

STATISTICAL TESTS

POLY 3	P=0.084	P=0.489N	P=0.500N	P=0.324
POLY 1.5	P=0.085	P=0.494N	P=0.501N	P=0.315
POLY 6	P=0.084	P=0.482N	P=0.500N	P=0.336
COCH-ARM / FISHERS	P=0.086	P=0.500N	P=0.500N	P=0.309
MAX-ISO-POLY-3	P=0.053	P=0.158N	P=0.159N	P=0.173

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pancreas
Atrophy**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.29	1/45.80	1/42.79	0/45.33
POLY-3 PERCENT (g)	2.3%	2.2%	2.3%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	609	718	723	---

STATISTICAL TESTS

POLY 3	P=0.308N	P=0.748N	P=0.758	P=0.491N
POLY 1.5	P=0.311N	P=0.754N	P=0.757	P=0.495N
POLY 6	P=0.304N	P=0.740N	P=0.761	P=0.485N
COCH-ARM / FISHERS	P=0.313N	P=0.753N	P=0.747	P=0.500N
MAX-ISO-POLY-3	P=0.335N	P=0.484N	P=0.496	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pancreas
Cyst**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.09	1/45.80	0/42.77	0/45.33
POLY-3 PERCENT (g)	2.3%	2.2%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	673	718	---	---

STATISTICAL TESTS

POLY 3	P=0.239N	P=0.747N	P=0.501N	P=0.490N
POLY 1.5	P=0.240N	P=0.753N	P=0.503N	P=0.494N
POLY 6	P=0.238N	P=0.738N	P=0.499N	P=0.483N
COCH-ARM / FISHERS	P=0.240N	P=0.753N	P=0.505N	P=0.500N
MAX-ISO-POLY-3	P=0.256N	P=0.482N	P=0.160N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Parathyroid Gland
Cyst**

LESION RATES

OVERALL (a)	0/28 (0%)	1/32 (3%)	1/25 (4%)	0/21 (0%)
POLY-3 RATE (b)	0/23.59	1/30.00	1/21.67	0/18.31
POLY-3 PERCENT (g)	0%	3.3%	4.6%	0%
TERMINAL (d)	0/17 (0%)	0/26 (0%)	0/17 (0%)	0/15 (0%)
FIRST INCIDENCE	---	484	609	---

STATISTICAL TESTS

POLY 3	P=0.665N	P=0.548	P=0.483	(e)
POLY 1.5	P=0.668N	P=0.538	P=0.480	(e)
POLY 6	P=0.658N	P=0.561	P=0.490	(e)
COCH-ARM / FISHERS	P=0.673N	P=0.533	P=0.472	(e)
MAX-ISO-POLY-3	P=0.447	P=0.208	P=0.150	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Penis
Inflammation**

LESION RATES

OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/2 (100%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	2/2.00
POLY-3 PERCENT (g)	0%	0%	0%	100%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	659

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis
Angiectasis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/42.59	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis
Cyst**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	3/49 (6%)	2/50 (4%)
POLY-3 RATE (b)	1/42.87	2/45.75	3/42.61	2/45.33
POLY-3 PERCENT (g)	2.3%	4.4%	7%	4.4%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	2/32 (6%)	2/37 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	723	729 (T)

STATISTICAL TESTS

POLY 3	P=0.429	P=0.523	P=0.303	P=0.519
POLY 1.5	P=0.418	P=0.513	P=0.300	P=0.511
POLY 6	P=0.445	P=0.537	P=0.308	P=0.532
COCH-ARM / FISHERS	P=0.405	P=0.500	P=0.301	P=0.500
MAX-ISO-POLY-3	P=0.376	P=0.305	P=0.152	P=0.302

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	7/50 (14%)	2/49 (4%)	6/50 (12%)
POLY-3 RATE (b)	0/42.87	7/45.80	2/42.59	6/45.33
POLY-3 PERCENT (g)	0%	15.3%	4.7%	13.2%
TERMINAL (d)	0/31 (0%)	6/38 (16%)	2/32 (6%)	6/37 (16%)
FIRST INCIDENCE	---	718	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.087	P=0.010**	P=0.235	P=0.018*
POLY 1.5	P=0.081	P=0.009**	P=0.234	P=0.017*
POLY 6	P=0.097	P=0.011*	P=0.239	P=0.020*
COCH-ARM / FISHERS	P=0.077	P=0.006**	P=0.242	P=0.013*
MAX-ISO-POLY-3	P=0.021*	P=0.004**	P=0.075	P=0.007**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Preputial Gland
Ectasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/43.20	2/45.43
POLY-3 PERCENT (g)	0%	0%	0%	4.4%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	715

STATISTICAL TESTS

POLY 3	P=0.046*	(e)	(e)	P=0.250
POLY 1.5	P=0.046*	(e)	(e)	P=0.244
POLY 6	P=0.047*	(e)	(e)	P=0.259
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.043*	(e)	(e)	P=0.089

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Preputial Gland
Inflammation**

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/42.87	1/45.75	1/43.39	0/45.33
POLY-3 PERCENT (g)	4.7%	2.2%	2.3%	0%
TERMINAL (d)	2/31 (7%)	1/38 (3%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	678	---

STATISTICAL TESTS

POLY 3	P=0.151N	P=0.477N	P=0.496N	P=0.225N
POLY 1.5	P=0.152N	P=0.487N	P=0.498N	P=0.230N
POLY 6	P=0.149N	P=0.463N	P=0.491N	P=0.217N
COCH-ARM / FISHERS	P=0.153N	P=0.500N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.121N	P=0.268N	P=0.278N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Seminal Vesicle
Dilatation**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/42.87	2/45.93	1/43.20	0/45.33
POLY-3 PERCENT (g)	2.3%	4.4%	2.3%	0%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	1/32 (3%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	684	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.238N	P=0.524	P=0.759N	P=0.489N
POLY 1.5	P=0.244N	P=0.513	P=0.760N	P=0.494N
POLY 6	P=0.230N	P=0.540	P=0.757N	P=0.482N
COCH-ARM / FISHERS	P=0.250N	P=0.500	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.243N	P=0.306	P=0.497N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Skin
Inflammation**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/49 (0%)	3/50 (6%)
POLY-3 RATE (b)	0/42.87	1/45.80	0/42.20	3/45.78
POLY-3 PERCENT (g)	0%	2.2%	0%	6.6%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/31 (0%)	1/37 (3%)
FIRST INCIDENCE	---	718	---	659

STATISTICAL TESTS

POLY 3	P=0.045*	P=0.513	(e)	P=0.131
POLY 1.5	P=0.044*	P=0.507	(e)	P=0.125
POLY 6	P=0.048*	P=0.522	(e)	P=0.140
COCH-ARM / FISHERS	P=0.043*	P=0.500	(e)	P=0.121
MAX-ISO-POLY-3	P=0.033*	P=0.175	(e)	P=0.048*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Skin
Ulcer**

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	5/49 (10%)	3/50 (6%)
POLY-3 RATE (b)	1/43.36	3/45.83	5/43.05	3/46.13
POLY-3 PERCENT (g)	2.3%	6.6%	11.6%	6.5%
TERMINAL (d)	0/31 (0%)	2/38 (5%)	3/31 (10%)	0/37 (0%)
FIRST INCIDENCE	584	710	508	554

STATISTICAL TESTS

POLY 3	P=0.307	P=0.325	P=0.099	P=0.328
POLY 1.5	P=0.293	P=0.316	P=0.098	P=0.318
POLY 6	P=0.330	P=0.339	P=0.101	P=0.343
COCH-ARM / FISHERS	P=0.275	P=0.309	P=0.098	P=0.309
MAX-ISO-POLY-3	P=0.177	P=0.175	P=0.043*	P=0.177

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Spleen
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	3/49 (6%)	2/50 (4%)
POLY-3 RATE (b)	0/42.87	2/45.75	3/43.16	2/45.57
POLY-3 PERCENT (g)	0%	4.4%	7%	4.4%
TERMINAL (d)	0/31 (0%)	2/38 (5%)	2/32 (6%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	618	680

STATISTICAL TESTS

POLY 3	P=0.264	P=0.252	P=0.119	P=0.251
POLY 1.5	P=0.252	P=0.245	P=0.117	P=0.245
POLY 6	P=0.282	P=0.262	P=0.123	P=0.261
COCH-ARM / FISHERS	P=0.238	P=0.247	P=0.117	P=0.247
MAX-ISO-POLY-3	P=0.150	P=0.090	P=0.039*	P=0.089

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Spleen
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/42.77	0/45.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Forestomach
Hyperplasia**

LESION RATES

OVERALL (a)	3/50 (6%)	4/50 (8%)	6/50 (12%)	4/50 (8%)
POLY-3 RATE (b)	3/44.15	4/45.75	6/44.00	4/45.93
POLY-3 PERCENT (g)	6.8%	8.7%	13.6%	8.7%
TERMINAL (d)	0/31 (0%)	4/38 (11%)	4/32 (13%)	2/37 (5%)
FIRST INCIDENCE	589	729 (T)	609	555

STATISTICAL TESTS

POLY 3	P=0.442	P=0.519	P=0.239	P=0.522
POLY 1.5	P=0.431	P=0.511	P=0.240	P=0.512
POLY 6	P=0.456	P=0.531	P=0.240	P=0.535
COCH-ARM / FISHERS	P=0.418	P=0.500	P=0.243	P=0.500
MAX-ISO-POLY-3	P=0.398	P=0.367	P=0.145	P=0.369

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Forestomach
Inflammation**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.68	2/46.65	0/43.20	0/45.33
POLY-3 PERCENT (g)	4.6%	4.3%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	609	536	---	---

STATISTICAL TESTS

POLY 3	P=0.087N	P=0.670N	P=0.239N	P=0.229N
POLY 1.5	P=0.087N	P=0.680N	P=0.239N	P=0.233N
POLY 6	P=0.086N	P=0.656N	P=0.240N	P=0.224N
COCH-ARM / FISHERS	P=0.088N	P=0.691N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.120N	P=0.473N	P=0.078N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Glandular
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	3/43.20	0/45.33
POLY-3 PERCENT (g)	0%	0%	7%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	3/32 (9%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.575	(e)	P=0.120	(e)
POLY 1.5	P=0.564	(e)	P=0.119	(e)
POLY 6	P=0.590	(e)	P=0.121	(e)
COCH-ARM / FISHERS	P=0.549	(e)	P=0.121	(e)
MAX-ISO-POLY-3	P=0.178	(e)	P=0.039*	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Testes
Degeneration**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.87	2/45.75	1/43.22	0/45.33
POLY-3 PERCENT (g)	0%	4.4%	2.3%	0%
TERMINAL (d)	0/31 (0%)	2/38 (5%)	0/32 (0%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	723	---

STATISTICAL TESTS

POLY 3	P=0.444N	P=0.252	P=0.502	(e)
POLY 1.5	P=0.454N	P=0.245	P=0.501	(e)
POLY 6	P=0.429N	P=0.262	P=0.504	(e)
COCH-ARM / FISHERS	P=0.466N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.341N	P=0.090	P=0.161	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Thymus
Cyst**

LESION RATES

OVERALL (a)	1/38 (3%)	0/36 (0%)	2/36 (6%)	2/37 (5%)
POLY-3 RATE (b)	1/33.33	0/33.70	2/31.94	2/35.01
POLY-3 PERCENT (g)	3%	0%	6.3%	5.7%
TERMINAL (d)	1/26 (4%)	0/29 (0%)	2/25 (8%)	1/30 (3%)
FIRST INCIDENCE	729 (T)	---	729 (T)	554

STATISTICAL TESTS

POLY 3	P=0.263	P=0.498N	P=0.485	P=0.517
POLY 1.5	P=0.256	P=0.503N	P=0.483	P=0.506
POLY 6	P=0.272	P=0.491N	P=0.489	P=0.532
COCH-ARM / FISHERS	P=0.246	P=0.514N	P=0.479	P=0.490
MAX-ISO-POLY-3	P=0.279	P=0.162N	P=0.269	P=0.300

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Thyroid Gland
Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	2/48 (4%)	1/49 (2%)
POLY-3 RATE (b)	0/42.87	1/45.75	2/42.10	1/44.89
POLY-3 PERCENT (g)	0%	2.2%	4.8%	2.2%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	1/31 (3%)	0/36 (0%)
FIRST INCIDENCE	---	729 (T)	506	554

STATISTICAL TESTS

POLY 3	P=0.390	P=0.513	P=0.233	P=0.509
POLY 1.5	P=0.378	P=0.507	P=0.230	P=0.503
POLY 6	P=0.407	P=0.521	P=0.237	P=0.518
COCH-ARM / FISHERS	P=0.362	P=0.500	P=0.237	P=0.495
MAX-ISO-POLY-3	P=0.238	P=0.174	P=0.074	P=0.171

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Thyroid Gland: Follicular Cell
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/48 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/42.87	0/45.75	0/41.44	0/44.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/31 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Tooth: Dentine Malformation

LESION RATES

OVERALL (a)	4/6 (67%)	2/6 (33%)	5/8 (63%)	5/5 (100%)
POLY-3 RATE (b)	4/5.62	2/5.51	5/7.98	5/5.00
POLY-3 PERCENT (g)	71.2%	36.3%	62.7%	100%
TERMINAL (d)	4/5 (80%)	1/3 (33%)	3/5 (60%)	4/4 (100%)
FIRST INCIDENCE	729 (T)	684	678	555

STATISTICAL TESTS

POLY 3	P=0.126	P=0.285N	P=0.595N	P=0.317
POLY 1.5	P=0.114	P=0.286N	P=0.618N	P=0.287
POLY 6	P=0.150	P=0.286N	P=0.559N	P=0.374
COCH-ARM / FISHERS	P=0.109	P=0.284N	P=0.657N	P=0.273
MAX-ISO-POLY-3	P=0.076	P=0.123N	P=0.387N	P=0.085

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex
Accessory Adrenal Cortical Nodule**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	2/43.50	0/43.30	3/47.62	1/47.37
POLY-3 PERCENT (g)	4.6%	0%	6.3%	2.1%
TERMINAL (d)	2/32 (6%)	0/35 (0%)	2/36 (6%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	---	722	731 (T)

STATISTICAL TESTS

POLY 3	P=0.513N	P=0.238N	P=0.541	P=0.470N
POLY 1.5	P=0.526N	P=0.237N	P=0.527	P=0.479N
POLY 6	P=0.499N	P=0.239N	P=0.558	P=0.461N
COCH-ARM / FISHERS	P=0.550N	P=0.247N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.423N	P=0.077N	P=0.367	P=0.264N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	2/43.97	1/47.59	0/47.37
POLY-3 PERCENT (g)	0%	4.6%	2.1%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	---	627	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.435N	P=0.239	P=0.518	(e)
POLY 1.5	P=0.444N	P=0.239	P=0.512	(e)
POLY 6	P=0.425N	P=0.241	P=0.525	(e)
COCH-ARM / FISHERS	P=0.466N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.334N	P=0.078	P=0.180	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex
Hyperplasia**

LESION RATES

OVERALL (a)	5/50 (10%)	3/50 (6%)	8/50 (16%)	7/50 (14%)
POLY-3 RATE (b)	5/43.50	3/43.30	8/47.59	7/47.37
POLY-3 PERCENT (g)	11.5%	6.9%	16.8%	14.8%
TERMINAL (d)	5/32 (16%)	3/35 (9%)	8/36 (22%)	7/39 (18%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.258	P=0.358N	P=0.336	P=0.440
POLY 1.5	P=0.237	P=0.355N	P=0.316	P=0.421
POLY 6	P=0.281	P=0.361N	P=0.362	P=0.461
COCH-ARM / FISHERS	P=0.198	P=0.357N	P=0.277	P=0.380
MAX-ISO-POLY-3	P=0.295	P=0.233N	P=0.245	P=0.329

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex
Hypertrophy**

LESION RATES

OVERALL (a)	10/50 (20%)	13/50 (26%)	7/50 (14%)	8/50 (16%)
POLY-3 RATE (b)	10/44.49	13/43.30	7/47.59	8/47.37
POLY-3 PERCENT (g)	22.5%	30%	14.7%	16.9%
TERMINAL (d)	6/32 (19%)	13/35 (37%)	7/36 (19%)	8/39 (21%)
FIRST INCIDENCE	533	731 (T)	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.163N	P=0.287	P=0.245N	P=0.341N
POLY 1.5	P=0.179N	P=0.305	P=0.261N	P=0.356N
POLY 6	P=0.149N	P=0.265	P=0.228N	P=0.328N
COCH-ARM / FISHERS	P=0.218N	P=0.318	P=0.298N	P=0.398N
MAX-ISO-POLY-3	P=0.183N	P=0.213	P=0.177N	P=0.257N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Cortex
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	3/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	6.3%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	0/39 (0%)
FIRST INCIDENCE	---	---	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.603	(e)	P=0.136	(e)
POLY 1.5	P=0.586	(e)	P=0.130	(e)
POLY 6	P=0.622	(e)	P=0.143	(e)
COCH-ARM / FISHERS	P=0.549	(e)	P=0.121	(e)
MAX-ISO-POLY-3	P=0.201	(e)	P=0.052	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Adrenal Medulla
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	3/49 (6%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	3/46.37
POLY-3 PERCENT (g)	0%	0%	0%	6.5%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	3/38 (8%)
FIRST INCIDENCE	---	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.012*	(e)	(e)	P=0.131
POLY 1.5	P=0.011*	(e)	(e)	P=0.126
POLY 6	P=0.012*	(e)	(e)	P=0.136
COCH-ARM / FISHERS	P=0.011*	(e)	(e)	P=0.117
MAX-ISO-POLY-3	P=0.014*	(e)	(e)	P=0.049*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Brain
Atrophy**

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/44.14	1/43.30	1/47.59	0/47.37
POLY-3 PERCENT (g)	4.5%	2.3%	2.1%	0%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	592	731 (T)	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.142N	P=0.507N	P=0.474N	P=0.222N
POLY 1.5	P=0.146N	P=0.502N	P=0.482N	P=0.226N
POLY 6	P=0.138N	P=0.512N	P=0.464N	P=0.218N
COCH-ARM / FISHERS	P=0.153N	P=0.500N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.121N	P=0.288N	P=0.266N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Eye
Cataract**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	1/47.81	0/47.37
POLY-3 PERCENT (g)	0%	0%	2.1%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	673	---

STATISTICAL TESTS

POLY 3	P=0.732	(e)	P=0.519	(e)
POLY 1.5	P=0.722	(e)	P=0.512	(e)
POLY 6	P=0.743	(e)	P=0.527	(e)
COCH-ARM / FISHERS	P=0.701	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.417	(e)	P=0.182	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Eye: Cornea
Inflammation Chronic**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/43.52	0/43.30	0/47.59	1/47.37
POLY-3 PERCENT (g)	4.6%	0%	0%	2.1%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	0/36 (0%)	1/39 (3%)
FIRST INCIDENCE	726	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.456N	P=0.238N	P=0.218N	P=0.471N
POLY 1.5	P=0.459N	P=0.237N	P=0.224N	P=0.480N
POLY 6	P=0.454N	P=0.239N	P=0.210N	P=0.461N
COCH-ARM / FISHERS	P=0.461N	P=0.247N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.130N	P=0.077N	P=0.076N	P=0.264N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Harderian Gland
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	1/43.30	2/47.59	0/47.37
POLY-3 PERCENT (g)	0%	2.3%	4.2%	0%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	2/36 (6%)	0/39 (0%)
FIRST INCIDENCE	---	731 (T)	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.580N	P=0.499	P=0.258	(e)
POLY 1.5	P=0.591N	P=0.500	P=0.251	(e)
POLY 6	P=0.568N	P=0.498	P=0.267	(e)
COCH-ARM / FISHERS	P=0.615N	P=0.500	P=0.247	(e)
MAX-ISO-POLY-3	P=0.343N	P=0.158	P=0.096	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Heart
Cardiomyopathy**

LESION RATES

OVERALL (a)	5/50 (10%)	2/50 (4%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	5/43.80	2/43.30	3/47.59	1/47.37
POLY-3 PERCENT (g)	11.4%	4.6%	6.3%	2.1%
TERMINAL (d)	4/32 (13%)	2/35 (6%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	649	731 (T)	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.077N	P=0.220N	P=0.312N	P=0.084N
POLY 1.5	P=0.082N	P=0.217N	P=0.326N	P=0.089N
POLY 6	P=0.071N	P=0.224N	P=0.295N	P=0.080N
COCH-ARM / FISHERS	P=0.094N	P=0.218N	P=0.357N	P=0.102N
MAX-ISO-POLY-3	P=0.056N	P=0.123N	P=0.205N	P=0.041N*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Heart: Artery
Inflammation**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	2/43.52	0/47.59	1/47.41
POLY-3 PERCENT (g)	0%	4.6%	0%	2.1%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	673	---	719

STATISTICAL TESTS

POLY 3	P=0.565	P=0.237	(e)	P=0.517
POLY 1.5	P=0.556	P=0.238	(e)	P=0.512
POLY 6	P=0.575	P=0.237	(e)	P=0.523
COCH-ARM / FISHERS	P=0.534	P=0.247	(e)	P=0.500
MAX-ISO-POLY-3	P=0.355	P=0.076	(e)	P=0.180

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Heart: Atrium
Thrombosis

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Heart: Capillary
Hyperplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.29	0/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	4.5%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	584	---	---	---

STATISTICAL TESTS

POLY 3	P=0.111N	P=0.242N	P=0.222N	P=0.223N
POLY 1.5	P=0.113N	P=0.239N	P=0.226N	P=0.226N
POLY 6	P=0.110N	P=0.246N	P=0.216N	P=0.219N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.081N	P=0.076N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Intestine Small, Ileum
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	1/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	2.1%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	---	---	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.732	(e)	P=0.518	(e)
POLY 1.5	P=0.722	(e)	P=0.512	(e)
POLY 6	P=0.744	(e)	P=0.525	(e)
COCH-ARM / FISHERS	P=0.701	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.416	(e)	P=0.180	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Islets, Pancreatic
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	1/47.37
POLY-3 PERCENT (g)	0%	0%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	1/39 (3%)
FIRST INCIDENCE	---	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.213	(e)	(e)	P=0.517
POLY 1.5	P=0.209	(e)	(e)	P=0.512
POLY 6	P=0.218	(e)	(e)	P=0.523
COCH-ARM / FISHERS	P=0.200	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.153	(e)	(e)	P=0.179

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney
Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	1/43.60	1/47.59	0/47.37
POLY-3 PERCENT (g)	0%	2.3%	2.1%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	---	649	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.573N	P=0.500	P=0.518	(e)
POLY 1.5	P=0.580N	P=0.501	P=0.512	(e)
POLY 6	P=0.565N	P=0.501	P=0.525	(e)
COCH-ARM / FISHERS	P=0.597N	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.417N	P=0.159	P=0.180	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney
Infarct**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	4/50 (8%)	6/50 (12%)
POLY-3 RATE (b)	2/43.50	2/43.30	4/47.59	6/47.47
POLY-3 PERCENT (g)	4.6%	4.6%	8.4%	12.6%
TERMINAL (d)	2/32 (6%)	2/35 (6%)	4/36 (11%)	5/39 (13%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	704

STATISTICAL TESTS

POLY 3	P=0.075	P=0.693	P=0.380	P=0.163
POLY 1.5	P=0.068	P=0.693N	P=0.365	P=0.154
POLY 6	P=0.082	P=0.691	P=0.397	P=0.174
COCH-ARM / FISHERS	P=0.056	P=0.691N	P=0.339	P=0.134
MAX-ISO-POLY-3	P=0.117	P=0.497	P=0.244	P=0.097

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney
Metaplasia Osseous**

LESION RATES

OVERALL (a)	8/50 (16%)	3/50 (6%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	8/43.80	3/43.52	1/47.59	4/47.65
POLY-3 PERCENT (g)	18.3%	6.9%	2.1%	8.4%
TERMINAL (d)	7/32 (22%)	2/35 (6%)	1/36 (3%)	3/39 (8%)
FIRST INCIDENCE	649	673	731 (T)	653

STATISTICAL TESTS

POLY 3	P=0.122N	P=0.099N	P=0.011N*	P=0.138N
POLY 1.5	P=0.129N	P=0.097N	P=0.012N*	P=0.150N
POLY 6	P=0.115N	P=0.100N	P=0.009N**	P=0.126N
COCH-ARM / FISHERS	P=0.146N	P=0.100N	P=0.015N*	P=0.178N
MAX-ISO-POLY-3	P=0.024N*	P=0.053N	P=0.005N**	P=0.090N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Kidney
Nephropathy**

LESION RATES

OVERALL (a)	39/50 (78%)	40/50 (80%)	43/50 (86%)	46/50 (92%)
POLY-3 RATE (b)	39/46.98	40/45.82	43/48.62	46/50.00
POLY-3 PERCENT (g)	83%	87.3%	88.5%	92%
TERMINAL (d)	28/32 (88%)	34/35 (97%)	33/36 (92%)	35/39 (90%)
FIRST INCIDENCE	522	533	673	610

STATISTICAL TESTS

POLY 3	P=0.107	P=0.377	P=0.313	P=0.143
POLY 1.5	P=0.068	P=0.459	P=0.294	P=0.104
POLY 6	P=0.182	P=0.266	P=0.336	P=0.202
COCH-ARM / FISHERS	P=0.025*	P=0.500	P=0.218	P=0.045*
MAX-ISO-POLY-3	P=0.127	P=0.267	P=0.218	P=0.089

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Larynx
Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	1/43.50	2/43.30	1/47.64	3/47.37
POLY-3 PERCENT (g)	2.3%	4.6%	2.1%	6.3%
TERMINAL (d)	1/32 (3%)	2/35 (6%)	0/36 (0%)	3/39 (8%)
FIRST INCIDENCE	731 (T)	731 (T)	718	731 (T)

STATISTICAL TESTS

POLY 3	P=0.267	P=0.498	P=0.740N	P=0.336
POLY 1.5	P=0.257	P=0.501	P=0.747N	P=0.327
POLY 6	P=0.278	P=0.496	P=0.731N	P=0.347
COCH-ARM / FISHERS	P=0.236	P=0.500	P=0.753N	P=0.309
MAX-ISO-POLY-3	P=0.275	P=0.279	P=0.474N	P=0.186

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Basophilic Focus**

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	6/50 (12%)	1/50 (2%)
POLY-3 RATE (b)	1/43.50	3/43.30	6/47.62	1/47.37
POLY-3 PERCENT (g)	2.3%	6.9%	12.6%	2.1%
TERMINAL (d)	1/32 (3%)	3/35 (9%)	5/36 (14%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	731 (T)	722	731 (T)

STATISTICAL TESTS

POLY 3	P=0.491N	P=0.303	P=0.072	P=0.741N
POLY 1.5	P=0.513N	P=0.306	P=0.067	P=0.747N
POLY 6	P=0.468N	P=0.301	P=0.079	P=0.735N
COCH-ARM / FISHERS	P=0.559N	P=0.309	P=0.056	P=0.753N
MAX-ISO-POLY-3	P=0.245N	P=0.153	P=0.037*	P=0.476N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver
Clear Cell Focus

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.50	0/43.30	2/47.81	0/47.37
POLY-3 PERCENT (g)	2.3%	0%	4.2%	0%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	---	673	---

STATISTICAL TESTS

POLY 3	P=0.427N	P=0.501N	P=0.533	P=0.483N
POLY 1.5	P=0.437N	P=0.500N	P=0.522	P=0.488N
POLY 6	P=0.417N	P=0.502N	P=0.547	P=0.477N
COCH-ARM / FISHERS	P=0.456N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.332N	P=0.160N	P=0.316	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Congestion**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver
Cyst

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.50	2/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	4.6%	0%	0%
TERMINAL (d)	1/32 (3%)	2/35 (6%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.181N	P=0.498	P=0.482N	P=0.483N
POLY 1.5	P=0.184N	P=0.501	P=0.488N	P=0.488N
POLY 6	P=0.178N	P=0.496	P=0.475N	P=0.477N
COCH-ARM / FISHERS	P=0.193N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.171N	P=0.279	P=0.158N	P=0.158N

TDMS No. 99017 - 06
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Diethylamine
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008
 Time Report Requested: 13:20:12
 First Dose M/F: 08/18/03 / 08/18/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver
 Degeneration Fatty

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.50	1/43.67	0/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	2.3%	0%	0%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	627	---	---

STATISTICAL TESTS

POLY 3	P=0.233N	P=0.760N	P=0.482N	P=0.483N
POLY 1.5	P=0.235N	P=0.759N	P=0.488N	P=0.488N
POLY 6	P=0.231N	P=0.760N	P=0.475N	P=0.477N
COCH-ARM / FISHERS	P=0.239N	P=0.753N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.255N	P=0.498N	P=0.158N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Eosinophilic Focus**

LESION RATES

OVERALL (a)	4/50 (8%)	7/50 (14%)	8/50 (16%)	2/50 (4%)
POLY-3 RATE (b)	4/43.50	7/43.30	8/47.64	2/47.37
POLY-3 PERCENT (g)	9.2%	16.2%	16.8%	4.2%
TERMINAL (d)	4/32 (13%)	7/35 (20%)	7/36 (19%)	2/39 (5%)
FIRST INCIDENCE	731 (T)	731 (T)	718	731 (T)

STATISTICAL TESTS

POLY 3	P=0.167N	P=0.257	P=0.224	P=0.299N
POLY 1.5	P=0.186N	P=0.262	P=0.208	P=0.311N
POLY 6	P=0.148N	P=0.252	P=0.245	P=0.286N
COCH-ARM / FISHERS	P=0.229N	P=0.262	P=0.178	P=0.339N
MAX-ISO-POLY-3	P=0.121N	P=0.165	P=0.153	P=0.181N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/44.29	2/43.97	0/47.59	1/47.37
POLY-3 PERCENT (g)	4.5%	4.6%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	1/39 (3%)
FIRST INCIDENCE	584	627	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.287N	P=0.691	P=0.222N	P=0.477N
POLY 1.5	P=0.291N	P=0.694N	P=0.226N	P=0.483N
POLY 6	P=0.284N	P=0.690	P=0.216N	P=0.471N
COCH-ARM / FISHERS	P=0.300N	P=0.691N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.262N	P=0.496	P=0.076N	P=0.268N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Liver
Mixed Cell Focus**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	0/43.50	0/43.30	2/47.59	2/47.47
POLY-3 PERCENT (g)	0%	0%	4.2%	4.2%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	2/36 (6%)	1/39 (3%)
FIRST INCIDENCE	---	---	731 (T)	704

STATISTICAL TESTS

POLY 3	P=0.106	(e)	P=0.258	P=0.257
POLY 1.5	P=0.099	(e)	P=0.251	P=0.251
POLY 6	P=0.113	(e)	P=0.267	P=0.264
COCH-ARM / FISHERS	P=0.088	(e)	P=0.247	P=0.247
MAX-ISO-POLY-3	P=0.150	(e)	P=0.096	P=0.095

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver
Necrosis

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	3/50 (6%)	3/50 (6%)
POLY-3 RATE (b)	1/44.14	2/43.51	3/47.91	3/48.34
POLY-3 PERCENT (g)	2.3%	4.6%	6.3%	6.2%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	522	676	690	626

STATISTICAL TESTS

POLY 3	P=0.275	P=0.495	P=0.335	P=0.339
POLY 1.5	P=0.259	P=0.499	P=0.325	P=0.328
POLY 6	P=0.295	P=0.492	P=0.349	P=0.352
COCH-ARM / FISHERS	P=0.228	P=0.500	P=0.309	P=0.309
MAX-ISO-POLY-3	P=0.324	P=0.278	P=0.185	P=0.188

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Liver
Tension Lipidosis

LESION RATES

OVERALL (a)	5/50 (10%)	8/50 (16%)	3/50 (6%)	9/50 (18%)
POLY-3 RATE (b)	5/43.76	8/44.07	3/47.86	9/47.64
POLY-3 PERCENT (g)	11.4%	18.2%	6.3%	18.9%
TERMINAL (d)	3/32 (9%)	6/35 (17%)	2/36 (6%)	8/39 (21%)
FIRST INCIDENCE	690	564	659	656

STATISTICAL TESTS

POLY 3	P=0.271	P=0.279	P=0.309N	P=0.243
POLY 1.5	P=0.254	P=0.281	P=0.325N	P=0.227
POLY 6	P=0.288	P=0.277	P=0.290N	P=0.259
COCH-ARM / FISHERS	P=0.220	P=0.277	P=0.357N	P=0.194
MAX-ISO-POLY-3	P=0.256	P=0.188	P=0.203N	P=0.172

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung
Hemorrhage**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	1/43.51	0/47.59	1/47.37
POLY-3 PERCENT (g)	0%	2.3%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	1/39 (3%)
FIRST INCIDENCE	---	676	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.427	P=0.500	(e)	P=0.517
POLY 1.5	P=0.420	P=0.501	(e)	P=0.512
POLY 6	P=0.435	P=0.500	(e)	P=0.523
COCH-ARM / FISHERS	P=0.403	P=0.500	(e)	P=0.500
MAX-ISO-POLY-3	P=0.289	P=0.159	(e)	P=0.179

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung
Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	1/43.64	2/44.53	3/47.59	1/47.37
POLY-3 PERCENT (g)	2.3%	4.5%	6.3%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	695	444	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.535N	P=0.507	P=0.337	P=0.742N
POLY 1.5	P=0.548N	P=0.506	P=0.327	P=0.748N
POLY 6	P=0.522N	P=0.508	P=0.350	P=0.736N
COCH-ARM / FISHERS	P=0.577N	P=0.500	P=0.309	P=0.753N
MAX-ISO-POLY-3	P=0.469N	P=0.288	P=0.187	P=0.477N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung: Alveolar Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	1/43.30	3/47.59	1/47.37
POLY-3 PERCENT (g)	0%	2.3%	6.3%	2.1%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	---	731 (T)	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.406	P=0.499	P=0.136	P=0.517
POLY 1.5	P=0.390	P=0.500	P=0.130	P=0.512
POLY 6	P=0.424	P=0.498	P=0.143	P=0.523
COCH-ARM / FISHERS	P=0.355	P=0.500	P=0.121	P=0.500
MAX-ISO-POLY-3	P=0.191	P=0.158	P=0.052	P=0.179

TDMS No. 99017 - 06
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Diethylamine
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008
 Time Report Requested: 13:20:12
 First Dose M/F: 08/18/03 / 08/18/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lung: Arteriole
 Inflammation Chronic**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	1/47.41
POLY-3 PERCENT (g)	0%	0%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	719

STATISTICAL TESTS

POLY 3	P=0.213	(e)	(e)	P=0.517
POLY 1.5	P=0.209	(e)	(e)	P=0.512
POLY 6	P=0.218	(e)	(e)	P=0.523
COCH-ARM / FISHERS	P=0.200	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.154	(e)	(e)	P=0.180

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lymph Node, Mandibular
Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	2/23 (9%)	0/40 (0%)	0/30 (0%)	1/33 (3%)
POLY-3 RATE (b)	2/19.81	0/34.35	0/28.96	1/31.51
POLY-3 PERCENT (g)	10.1%	0%	0%	3.2%
TERMINAL (d)	0/11 (0%)	0/28 (0%)	0/21 (0%)	0/26 (0%)
FIRST INCIDENCE	584	---	---	635

STATISTICAL TESTS

POLY 3	P=0.412N	P=0.122N	P=0.156N	P=0.341N
POLY 1.5	P=0.416N	P=0.120N	P=0.161N	P=0.349N
POLY 6	P=0.411N	P=0.122N	P=0.150N	P=0.331N
COCH-ARM / FISHERS	P=0.415N	P=0.130N	P=0.184N	P=0.365N
MAX-ISO-POLY-3	P=0.062N	P=0.043N*	P=0.058N	P=0.186N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Lymph Node, Mesenteric
Infiltration Cellular**

LESION RATES

OVERALL (a)	0/50 (0%)	0/46 (0%)	0/46 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/43.50	0/40.48	0/43.75	0/46.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/34 (0%)	0/33 (0%)	0/38 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Mesentery
Inflammation Chronic**

LESION RATES

OVERALL (a)	0/12 (0%)	1/16 (6%)	0/15 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/11.77	1/15.29	0/14.28	0/8.85
POLY-3 PERCENT (g)	0%	6.5%	0%	0%
TERMINAL (d)	0/9 (0%)	0/13 (0%)	0/8 (0%)	0/6 (0%)
FIRST INCIDENCE	---	627	---	---

STATISTICAL TESTS

POLY 3	P=0.621N	P=0.552	(e)	(e)
POLY 1.5	P=0.620N	P=0.554	(e)	(e)
POLY 6	P=0.623N	P=0.550	(e)	(e)
COCH-ARM / FISHERS	P=0.620N	P=0.571	(e)	(e)
MAX-ISO-POLY-3	P=0.477N	P=0.204	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Mesentery: Fat
Necrosis**

LESION RATES

OVERALL (a)	10/12 (83%)	12/16 (75%)	11/15 (73%)	6/10 (60%)
POLY-3 RATE (b)	10/11.88	12/15.59	11/14.77	6/9.22
POLY-3 PERCENT (g)	84.2%	77%	74.5%	65.1%
TERMINAL (d)	9/9 (100%)	10/13 (77%)	6/8 (75%)	5/6 (83%)
FIRST INCIDENCE	704	627	680	626

STATISTICAL TESTS

POLY 3	P=0.218N	P=0.505N	P=0.448N	P=0.301N
POLY 1.5	P=0.192N	P=0.492N	P=0.444N	P=0.266N
POLY 6	P=0.270N	P=0.518N	P=0.455N	P=0.372N
COCH-ARM / FISHERS	P=0.161N	P=0.479N	P=0.443N	P=0.229N
MAX-ISO-POLY-3	P=0.279N	P=0.329N	P=0.283N	P=0.166N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose
Inflammation**

LESION RATES

OVERALL (a)	2/50 (4%)	1/49 (2%)	3/50 (6%)	9/50 (18%)
POLY-3 RATE (b)	2/43.60	1/43.08	3/47.73	9/48.59
POLY-3 PERCENT (g)	4.6%	2.3%	6.3%	18.5%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	1/36 (3%)	4/39 (10%)
FIRST INCIDENCE	705	613	709	626

STATISTICAL TESTS

POLY 3	P=0.003**	P=0.504N	P=0.541	P=0.039*
POLY 1.5	P=0.003**	P=0.504N	P=0.527	P=0.034*
POLY 6	P=0.004**	P=0.503N	P=0.558	P=0.047*
COCH-ARM / FISHERS	P=0.002**	P=0.508N	P=0.500	P=0.026*
MAX-ISO-POLY-3	P=0.005**	P=0.284N	P=0.367	P=0.024*

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Glands, Respiratory Epithelium
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	16/50 (32%)	28/49 (57%)	45/50 (90%)	42/50 (84%)
POLY-3 RATE (b)	16/44.47	28/44.10	45/49.72	42/49.91
POLY-3 PERCENT (g)	36%	63.5%	90.5%	84.2%
TERMINAL (d)	11/32 (34%)	23/35 (66%)	33/36 (92%)	32/39 (82%)
FIRST INCIDENCE	584	600	414	610

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.006**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.007**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.006**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.010**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.003**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Glands, Respiratory Epithelium
Hyperplasia**

LESION RATES

OVERALL (a)	43/50 (86%)	45/49 (92%)	47/50 (94%)	50/50 (100%)
POLY-3 RATE (b)	43/48.26	45/47.68	47/49.94	50/50.00
POLY-3 PERCENT (g)	89.1%	94.4%	94.1%	100%
TERMINAL (d)	27/32 (84%)	34/35 (97%)	34/36 (94%)	39/39 (100%)
FIRST INCIDENCE	522	313	414	610

STATISTICAL TESTS

POLY 3	P=0.016*	P=0.275	P=0.296	P=0.021*
POLY 1.5	P=0.013*	P=0.322	P=0.271	P=0.017*
POLY 6	P=0.020*	P=0.203	P=0.312	P=0.026*
COCH-ARM / FISHERS	P=0.006**	P=0.274	P=0.159	P=0.006**
MAX-ISO-POLY-3	P=0.011*	P=0.162	P=0.188	P=0.007**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Glands, Respiratory Epithelium
Inflammation Chronic**

LESION RATES

OVERALL (a)	8/50 (16%)	11/49 (22%)	16/50 (32%)	22/50 (44%)
POLY-3 RATE (b)	8/44.87	11/43.89	16/48.44	22/48.95
POLY-3 PERCENT (g)	17.8%	25.1%	33%	45%
TERMINAL (d)	4/32 (13%)	7/35 (20%)	14/36 (39%)	15/39 (39%)
FIRST INCIDENCE	533	600	414	626

STATISTICAL TESTS

POLY 3	P=0.002**	P=0.284	P=0.073	P=0.004**
POLY 1.5	P<0.001**	P=0.289	P=0.065	P=0.003**
POLY 6	P=0.002**	P=0.284	P=0.081	P=0.005**
COCH-ARM / FISHERS	P<0.001**	P=0.288	P=0.050*	P=0.002**
MAX-ISO-POLY-3	P=0.002**	P=0.205	P=0.051	P=0.002**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	11/50 (22%)	19/49 (39%)	8/50 (16%)	17/50 (34%)
POLY-3 RATE (b)	11/43.64	19/43.96	8/47.93	17/48.20
POLY-3 PERCENT (g)	25.2%	43.2%	16.7%	35.3%
TERMINAL (d)	10/32 (31%)	16/35 (46%)	6/36 (17%)	14/39 (36%)
FIRST INCIDENCE	695	551	659	610

STATISTICAL TESTS

POLY 3	P=0.380	P=0.056	P=0.228N	P=0.206
POLY 1.5	P=0.341	P=0.056	P=0.254N	P=0.180
POLY 6	P=0.425	P=0.059	P=0.198N	P=0.239
COCH-ARM / FISHERS	P=0.268	P=0.055	P=0.306N	P=0.133
MAX-ISO-POLY-3	P=0.248	P=0.036*	P=0.169N	P=0.159

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium
Atrophy**

LESION RATES

OVERALL (a)	8/50 (16%)	29/49 (59%)	49/50 (98%)	50/50 (100%)
POLY-3 RATE (b)	8/45.01	29/45.91	49/49.94	50/50.00
POLY-3 PERCENT (g)	17.8%	63.2%	98.1%	100%
TERMINAL (d)	4/32 (13%)	20/35 (57%)	36/36 (100%)	39/39 (100%)
FIRST INCIDENCE	465	564	414	610

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium
Necrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	0/42.67	2/47.75	1/47.64
POLY-3 PERCENT (g)	0%	0%	4.2%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	709	656

STATISTICAL TESTS

POLY 3	P=0.290	(e)	P=0.259	P=0.518
POLY 1.5	P=0.277	(e)	P=0.251	P=0.512
POLY 6	P=0.304	(e)	P=0.268	P=0.525
COCH-ARM / FISHERS	P=0.253	(e)	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.210	(e)	P=0.096	P=0.181

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium
Respiratory Metaplasia**

LESION RATES

OVERALL (a)	4/50 (8%)	15/49 (31%)	48/50 (96%)	50/50 (100%)
POLY-3 RATE (b)	4/43.50	15/44.72	48/49.94	50/50.00
POLY-3 PERCENT (g)	9.2%	33.5%	96.1%	100%
TERMINAL (d)	4/32 (13%)	9/35 (26%)	35/36 (97%)	39/39 (100%)
FIRST INCIDENCE	731 (T)	564	414	610

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.004**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.004**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.005**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.004**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.002**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Olfactory Epithelium
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	5/49 (10%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	5/43.90	1/47.61	1/47.62
POLY-3 PERCENT (g)	0%	11.4%	2.1%	2.1%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	600	726	664

STATISTICAL TESTS

POLY 3	P=0.431N	P=0.031*	P=0.518	P=0.518
POLY 1.5	P=0.447N	P=0.030*	P=0.512	P=0.512
POLY 6	P=0.412N	P=0.033*	P=0.525	P=0.524
COCH-ARM / FISHERS	P=0.482N	P=0.027*	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.181	P=0.010**	P=0.181	P=0.181

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	20/50 (40%)	33/49 (67%)	47/50 (94%)	29/50 (58%)
POLY-3 RATE (b)	20/43.91	33/44.88	47/49.94	29/49.03
POLY-3 PERCENT (g)	45.6%	73.5%	94.1%	59.1%
TERMINAL (d)	17/32 (53%)	26/35 (74%)	34/36 (94%)	22/39 (56%)
FIRST INCIDENCE	690	600	414	610

STATISTICAL TESTS

POLY 3	P=0.238	P=0.004**	P<0.001**	P=0.131
POLY 1.5	P=0.145	P=0.004**	P<0.001**	P=0.098
POLY 6	P=0.379	P=0.005**	P<0.001**	P=0.182
COCH-ARM / FISHERS	P=0.059	P=0.006**	P<0.001**	P=0.055
MAX-ISO-POLY-3	P<0.001**	P=0.002**	P<0.001**	P=0.103

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium
Metaplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	13/50 (26%)	35/50 (70%)
POLY-3 RATE (b)	0/43.50	0/42.67	13/48.03	35/49.06
POLY-3 PERCENT (g)	0%	0%	27.1%	71.4%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	9/36 (25%)	28/39 (72%)
FIRST INCIDENCE	---	---	659	610

STATISTICAL TESTS

POLY 3	P<0.001**	(e)	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium
Necrosis**

LESION RATES

OVERALL (a)	1/50 (2%)	0/49 (0%)	6/50 (12%)	16/50 (32%)
POLY-3 RATE (b)	1/43.50	0/42.67	6/47.86	16/48.53
POLY-3 PERCENT (g)	2.3%	0%	12.5%	33%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	2/36 (6%)	11/39 (28%)
FIRST INCIDENCE	731 (T)	---	709	635

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.504N	P=0.073	P<0.001**
POLY 1.5	P<0.001**	P=0.503N	P=0.067	P<0.001**
POLY 6	P<0.001**	P=0.504N	P=0.082	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.505N	P=0.056	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.162N	P=0.038*	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium
Ulcer**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/43.50	0/42.67	0/47.59	2/47.65
POLY-3 PERCENT (g)	0%	0%	0%	4.2%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	684

STATISTICAL TESTS

POLY 3	P=0.051	(e)	(e)	P=0.258
POLY 1.5	P=0.049*	(e)	(e)	P=0.251
POLY 6	P=0.053	(e)	(e)	P=0.266
COCH-ARM / FISHERS	P=0.047*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.050*	(e)	(e)	P=0.096

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Respiratory Epithelium
Vacuolization Cytoplasmic**

LESION RATES

OVERALL (a)	0/50 (0%)	2/49 (4%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	2/43.45	2/47.68	1/47.62
POLY-3 PERCENT (g)	0%	4.6%	4.2%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	551	712	664

STATISTICAL TESTS

POLY 3	P=0.523	P=0.237	P=0.258	P=0.518
POLY 1.5	P=0.506	P=0.236	P=0.251	P=0.512
POLY 6	P=0.541	P=0.239	P=0.268	P=0.524
COCH-ARM / FISHERS	P=0.472	P=0.242	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.256	P=0.077	P=0.096	P=0.181

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Turbinate
Hyperostosis**

LESION RATES

OVERALL (a)	4/50 (8%)	23/49 (47%)	49/50 (98%)	50/50 (100%)
POLY-3 RATE (b)	4/44.15	23/44.97	49/49.98	50/50.00
POLY-3 PERCENT (g)	9.1%	51.2%	98%	100%
TERMINAL (d)	2/32 (6%)	17/35 (49%)	36/36 (100%)	39/39 (100%)
FIRST INCIDENCE	584	444	414	610

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Nose: Turbinate
Necrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	0/42.67	0/47.59	1/47.55
POLY-3 PERCENT (g)	0%	0%	0%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	684

STATISTICAL TESTS

POLY 3	P=0.214	(e)	(e)	P=0.518
POLY 1.5	P=0.210	(e)	(e)	P=0.512
POLY 6	P=0.219	(e)	(e)	P=0.524
COCH-ARM / FISHERS	P=0.201	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.156	(e)	(e)	P=0.180

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

Ovary
Cyst

LESION RATES

OVERALL (a)	8/49 (16%)	11/50 (22%)	7/50 (14%)	9/50 (18%)
POLY-3 RATE (b)	8/43.13	11/43.30	7/47.59	9/47.72
POLY-3 PERCENT (g)	18.6%	25.4%	14.7%	18.9%
TERMINAL (d)	7/32 (22%)	11/35 (31%)	7/36 (19%)	7/39 (18%)
FIRST INCIDENCE	533	731 (T)	731 (T)	664

STATISTICAL TESTS

POLY 3	P=0.439N	P=0.305	P=0.418N	P=0.591
POLY 1.5	P=0.468N	P=0.317	P=0.439N	P=0.569
POLY 6	P=0.407N	P=0.293	P=0.392N	P=0.595N
COCH-ARM / FISHERS	P=0.527N	P=0.323	P=0.483N	P=0.518
MAX-ISO-POLY-3	P=0.441N	P=0.222	P=0.320N	P=0.485

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Ovary
Hemorrhage**

LESION RATES

OVERALL (a)	2/49 (4%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	2/43.63	0/43.30	0/47.59	2/47.37
POLY-3 PERCENT (g)	4.6%	0%	0%	4.2%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	2/39 (5%)
FIRST INCIDENCE	47	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.525	P=0.239N	P=0.218N	P=0.664N
POLY 1.5	P=0.518	P=0.237N	P=0.224N	P=0.673N
POLY 6	P=0.532	P=0.240N	P=0.211N	P=0.655N
COCH-ARM / FISHERS	P=0.507	P=0.242N	P=0.242N	P=0.684N
MAX-ISO-POLY-3	P=0.261N	P=0.078N	P=0.075N	P=0.467N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pancreas
Atrophy**

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.50	3/43.67	1/47.59	1/47.37
POLY-3 PERCENT (g)	2.3%	6.9%	2.1%	2.1%
TERMINAL (d)	1/32 (3%)	2/35 (6%)	1/36 (3%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	627	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.416N	P=0.306	P=0.740N	P=0.741N
POLY 1.5	P=0.427N	P=0.308	P=0.747N	P=0.747N
POLY 6	P=0.406N	P=0.306	P=0.732N	P=0.735N
COCH-ARM / FISHERS	P=0.450N	P=0.309	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.424N	P=0.155	P=0.475N	P=0.476N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pancreas
Cyst**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/43.50	2/43.52	2/47.59	1/47.37
POLY-3 PERCENT (g)	2.3%	4.6%	4.2%	2.1%
TERMINAL (d)	1/32 (3%)	1/35 (3%)	2/36 (6%)	1/39 (3%)
FIRST INCIDENCE	731 (T)	673	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.519N	P=0.500	P=0.531	P=0.741N
POLY 1.5	P=0.531N	P=0.502	P=0.521	P=0.747N
POLY 6	P=0.507N	P=0.500	P=0.544	P=0.735N
COCH-ARM / FISHERS	P=0.557N	P=0.500	P=0.500	P=0.753N
MAX-ISO-POLY-3	P=0.542N	P=0.280	P=0.315	P=0.476N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Parathyroid Gland
Cyst**

LESION RATES

OVERALL (a)	0/23 (0%)	1/32 (3%)	2/33 (6%)	0/33 (0%)
POLY-3 RATE (b)	0/19.68	1/27.53	2/32.62	0/31.23
POLY-3 PERCENT (g)	0%	3.6%	6.1%	0%
TERMINAL (d)	0/15 (0%)	0/22 (0%)	2/27 (7%)	0/26 (0%)
FIRST INCIDENCE	---	677	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.506N	P=0.567	P=0.357	(e)
POLY 1.5	P=0.515N	P=0.569	P=0.346	(e)
POLY 6	P=0.499N	P=0.564	P=0.368	(e)
COCH-ARM / FISHERS	P=0.547N	P=0.582	P=0.343	(e)
MAX-ISO-POLY-3	P=0.391N	P=0.218	P=0.171	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis
Angiectasis**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	4/50 (8%)	2/49 (4%)
POLY-3 RATE (b)	1/43.50	0/43.30	4/47.61	2/46.41
POLY-3 PERCENT (g)	2.3%	0%	8.4%	4.3%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	3/36 (8%)	1/38 (3%)
FIRST INCIDENCE	731 (T)	---	726	719

STATISTICAL TESTS

POLY 3	P=0.279	P=0.501N	P=0.208	P=0.523
POLY 1.5	P=0.264	P=0.500N	P=0.198	P=0.513
POLY 6	P=0.296	P=0.502N	P=0.220	P=0.532
COCH-ARM / FISHERS	P=0.236	P=0.500N	P=0.181	P=0.492
MAX-ISO-POLY-3	P=0.170	P=0.160N	P=0.111	P=0.306

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis
Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)	2/49 (4%)
POLY-3 RATE (b)	0/43.50	0/43.30	3/47.59	2/46.37
POLY-3 PERCENT (g)	0%	0%	6.3%	4.3%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	2/38 (5%)
FIRST INCIDENCE	---	---	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.117	(e)	P=0.136	P=0.252
POLY 1.5	P=0.109	(e)	P=0.130	P=0.246
POLY 6	P=0.125	(e)	P=0.143	P=0.258
COCH-ARM / FISHERS	P=0.096	(e)	P=0.121	P=0.242
MAX-ISO-POLY-3	P=0.107	(e)	P=0.052	P=0.091

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Pituitary Gland: Pars Distalis
Hyperplasia**

LESION RATES

OVERALL (a)	8/50 (16%)	15/50 (30%)	16/50 (32%)	10/49 (20%)
POLY-3 RATE (b)	8/43.50	15/43.60	16/47.66	10/46.76
POLY-3 PERCENT (g)	18.4%	34.4%	33.6%	21.4%
TERMINAL (d)	8/32 (25%)	14/35 (40%)	14/36 (39%)	8/38 (21%)
FIRST INCIDENCE	731 (T)	649	718	635

STATISTICAL TESTS

POLY 3	P=0.484N	P=0.070	P=0.078	P=0.463
POLY 1.5	P=0.531N	P=0.074	P=0.067	P=0.436
POLY 6	P=0.431N	P=0.067	P=0.093	P=0.495
COCH-ARM / FISHERS	P=0.464	P=0.077	P=0.050*	P=0.379
MAX-ISO-POLY-3	P=0.192	P=0.042*	P=0.055	P=0.366

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Skin
Inflammation**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	1/43.80	0/43.30	3/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	0%	6.3%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	0/39 (0%)
FIRST INCIDENCE	649	---	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.456N	P=0.502N	P=0.336	P=0.484N
POLY 1.5	P=0.468N	P=0.500N	P=0.326	P=0.489N
POLY 6	P=0.443N	P=0.504N	P=0.347	P=0.480N
COCH-ARM / FISHERS	P=0.493N	P=0.500N	P=0.309	P=0.500N
MAX-ISO-POLY-3	P=0.282N	P=0.161N	P=0.185	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Skin
Ulcer**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.94	2/43.73	0/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	4.6%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	604	673	---	---

STATISTICAL TESTS

POLY 3	P=0.182N	P=0.498	P=0.484N	P=0.485N
POLY 1.5	P=0.185N	P=0.501	P=0.489N	P=0.489N
POLY 6	P=0.179N	P=0.497	P=0.478N	P=0.481N
COCH-ARM / FISHERS	P=0.193N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.171N	P=0.279	P=0.158N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Spleen
Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	2/50 (4%)	4/50 (8%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	2/43.64	4/44.18	4/47.64	2/47.71
POLY-3 PERCENT (g)	4.6%	9.1%	8.4%	4.2%
TERMINAL (d)	1/32 (3%)	1/35 (3%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	695	627	718	635

STATISTICAL TESTS

POLY 3	P=0.443N	P=0.343	P=0.379	P=0.661N
POLY 1.5	P=0.461N	P=0.342	P=0.365	P=0.671N
POLY 6	P=0.424N	P=0.346	P=0.395	P=0.650N
COCH-ARM / FISHERS	P=0.501N	P=0.339	P=0.339	P=0.691N
MAX-ISO-POLY-3	P=0.449N	P=0.206	P=0.243	P=0.465N

TDMS No. 99017 - 06
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Diethylamine
 CAS Number: 109-89-7

Date Report Requested: 10/23/2008
 Time Report Requested: 13:20:12
 First Dose M/F: 08/18/03 / 08/18/03
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Spleen
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/43.50	0/43.30	1/47.86	0/47.37
POLY-3 PERCENT (g)	4.6%	0%	2.1%	0%
TERMINAL (d)	2/32 (6%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	731 (T)	---	659	---

STATISTICAL TESTS

POLY 3	P=0.175N	P=0.238N	P=0.467N	P=0.219N
POLY 1.5	P=0.179N	P=0.237N	P=0.478N	P=0.224N
POLY 6	P=0.171N	P=0.239N	P=0.452N	P=0.213N
COCH-ARM / FISHERS	P=0.186N	P=0.247N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.077N	P=0.077N	P=0.263N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Forestomach
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	0/43.50	0/43.30	4/47.62	1/47.37
POLY-3 PERCENT (g)	0%	0%	8.4%	2.1%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	3/36 (8%)	1/39 (3%)
FIRST INCIDENCE	---	---	722	731 (T)

STATISTICAL TESTS

POLY 3	P=0.299	(e)	P=0.073	P=0.517
POLY 1.5	P=0.282	(e)	P=0.069	P=0.512
POLY 6	P=0.318	(e)	P=0.078	P=0.523
COCH-ARM / FISHERS	P=0.253	(e)	P=0.059	P=0.500
MAX-ISO-POLY-3	P=0.107	(e)	P=0.029*	P=0.179

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Forestomach
Inflammation**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.10	0/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	4.5%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	584	---	---	---

STATISTICAL TESTS

POLY 3	P=0.112N	P=0.241N	P=0.221N	P=0.222N
POLY 1.5	P=0.113N	P=0.238N	P=0.226N	P=0.226N
POLY 6	P=0.111N	P=0.244N	P=0.215N	P=0.217N
COCH-ARM / FISHERS	P=0.115N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.032N*	P=0.080N	P=0.076N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Stomach, Glandular
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.50	0/43.30	0/47.59	0/47.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	0/36 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Thymus
Cyst**

LESION RATES

OVERALL (a)	1/47 (2%)	0/47 (0%)	0/45 (0%)	0/47 (0%)
POLY-3 RATE (b)	1/41.66	0/41.15	0/42.73	0/44.64
POLY-3 PERCENT (g)	2.4%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/34 (0%)	0/33 (0%)	0/37 (0%)
FIRST INCIDENCE	604	---	---	---

STATISTICAL TESTS

POLY 3	P=0.311N	P=0.502N	P=0.495N	P=0.486N
POLY 1.5	P=0.311N	P=0.500N	P=0.499N	P=0.490N
POLY 6	P=0.311N	P=0.504N	P=0.490N	P=0.482N
COCH-ARM / FISHERS	P=0.308N	P=0.500N	P=0.511N	P=0.500N
MAX-ISO-POLY-3	P=0.125N	P=0.162N	P=0.161N	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Thyroid Gland
Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	7/50 (14%)	3/50 (6%)
POLY-3 RATE (b)	0/43.50	2/43.60	7/47.61	3/48.13
POLY-3 PERCENT (g)	0%	4.6%	14.7%	6.2%
TERMINAL (d)	0/32 (0%)	1/35 (3%)	6/36 (17%)	1/39 (3%)
FIRST INCIDENCE	---	649	726	610

STATISTICAL TESTS

POLY 3	P=0.164	P=0.238	P=0.011*	P=0.138
POLY 1.5	P=0.145	P=0.238	P=0.010**	P=0.132
POLY 6	P=0.187	P=0.237	P=0.012*	P=0.146
COCH-ARM / FISHERS	P=0.117	P=0.247	P=0.006**	P=0.121
MAX-ISO-POLY-3	P=0.039*	P=0.076	P=0.005**	P=0.054

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Thyroid Gland: Follicular Cell
Hyperplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/44.71	0/43.30	1/47.59	0/47.37
POLY-3 PERCENT (g)	4.5%	0%	2.1%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	1/36 (3%)	0/39 (0%)
FIRST INCIDENCE	465	---	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.175N	P=0.244N	P=0.478N	P=0.225N
POLY 1.5	P=0.179N	P=0.240N	P=0.485N	P=0.228N
POLY 6	P=0.171N	P=0.248N	P=0.470N	P=0.221N
COCH-ARM / FISHERS	P=0.186N	P=0.247N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.077N	P=0.083N	P=0.269N	P=0.076N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Tooth: Dentine
Malformation**

LESION RATES

OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/1 (0%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	0/0.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Uterus
Angiectasis**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	1/43.50	1/43.30	1/47.59	4/47.37
POLY-3 PERCENT (g)	2.3%	2.3%	2.1%	8.5%
TERMINAL (d)	1/32 (3%)	1/35 (3%)	1/36 (3%)	4/39 (10%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	731 (T)

STATISTICAL TESTS

POLY 3	P=0.079	P=0.760	P=0.740N	P=0.206
POLY 1.5	P=0.075	P=0.760N	P=0.747N	P=0.197
POLY 6	P=0.083	P=0.759	P=0.732N	P=0.215
COCH-ARM / FISHERS	P=0.067	P=0.753N	P=0.753N	P=0.181
MAX-ISO-POLY-3	P=0.110	P=0.498	P=0.475N	P=0.109

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Uterus
Inflammation Chronic**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.99	0/43.30	2/47.59	0/47.37
POLY-3 PERCENT (g)	2.3%	0%	4.2%	0%
TERMINAL (d)	0/32 (0%)	0/35 (0%)	2/36 (6%)	0/39 (0%)
FIRST INCIDENCE	584	---	731 (T)	---

STATISTICAL TESTS

POLY 3	P=0.429N	P=0.503N	P=0.527	P=0.485N
POLY 1.5	P=0.438N	P=0.501N	P=0.519	P=0.489N
POLY 6	P=0.419N	P=0.506N	P=0.538	P=0.481N
COCH-ARM / FISHERS	P=0.456N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.332N	P=0.162N	P=0.311	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Uterus
Thrombosis**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	2/43.58	0/43.30	0/47.59	3/47.37
POLY-3 PERCENT (g)	4.6%	0%	0%	6.3%
TERMINAL (d)	1/32 (3%)	0/35 (0%)	0/36 (0%)	3/39 (8%)
FIRST INCIDENCE	712	---	---	731 (T)

STATISTICAL TESTS

POLY 3	P=0.261	P=0.238N	P=0.218N	P=0.538
POLY 1.5	P=0.255	P=0.237N	P=0.224N	P=0.526
POLY 6	P=0.267	P=0.240N	P=0.211N	P=0.550
COCH-ARM / FISHERS	P=0.247	P=0.247N	P=0.247N	P=0.500
MAX-ISO-POLY-3	P=0.137	P=0.077N	P=0.076N	P=0.363

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	16 PPM	31 PPM	62.5 PPM

**Uterus: Endometrium
Hyperplasia Cystic**

LESION RATES

OVERALL (a)	26/50 (52%)	18/50 (36%)	21/50 (42%)	27/50 (54%)
POLY-3 RATE (b)	26/44.65	18/46.09	21/48.64	27/49.18
POLY-3 PERCENT (g)	58.2%	39.1%	43.2%	54.9%
TERMINAL (d)	21/32 (66%)	10/35 (29%)	15/36 (42%)	19/39 (49%)
FIRST INCIDENCE	592	533	659	610

STATISTICAL TESTS

POLY 3	P=0.439	P=0.048N*	P=0.103N	P=0.453N
POLY 1.5	P=0.385	P=0.057N	P=0.135N	P=0.522N
POLY 6	P=0.498	P=0.038N*	P=0.072N	P=0.372N
COCH-ARM / FISHERS	P=0.285	P=0.079N	P=0.212N	P=0.500
MAX-ISO-POLY-3	P=0.199N	P=0.032N*	P=0.078N	P=0.376N

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
 - (e) Value of Statistic cannot be computed.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***